Middle East Live

PARIS LA DÉFENSE - Friday, 31. March 2023 AETOSWire Print 

Thales, leader in advanced technologies, successfully experimented end-to-end encrypted phone calls, tested to be resilient in the Post Quantum era.
The pilot was performed with the Thales ‘Cryptosmart’ secure mobile app and 5G SIM cards installed in today's commercial smartphones, testing a mobile-to-mobile call, voice/data encryption, and user authentication.
Any data exchanged during the call is set to be resistant to Post Quantum attacks thanks to a hybrid cryptography approach, combining pre-quantum and post-quantum defence mechanisms.
 

(BUSINESS WIRE)--Thales, as a worldwide cybersecurity leader, has created the first real-world application of Post Quantum Cryptography (PQC) in its flagship secure ‘Cryptosmart’ mobile app, leveraging 5G SIM for PQC. In the pilot, hybrid cryptography (pre and post quantum crypto) was used in a phone call between two devices to protect the information exchanged during the call. Thales has invested and tested post-quantum cybersecurity technologies over the last decade in order to prepare for these emerging threats.

Even if today's quantum computer1 prototypes are still far from posing a threat to public key cryptography, it is critical to begin investigating resilient solutions. For example, there is a variant of "store now, decrypt later" attacks that consists in storing today's exchanged data and messages in order to decrypt these messages once Quantum Computers are available. This means the majority of digital infrastructure security based on public key cryptography (PKC) may already be vulnerable to a quantum attack.

Such threats are relevant for scenarios involving highly sensitive information, such as classified information exchanged over an encrypted phone call. To address these threats, Thales created a proof of concept to test the scalability and quality of its solutions, which range from 5G SIM cards to secure communication software.

This first real-world quantum protected mobile solution, which combines Thales' 'Cryptosmart' application and its 5G SIM, employs hybrid cryptography, as recommended by the NIST (National Institute of Standards and Technology). ‘CRYSTALS-Kyber’, one of the four algorithms selected by the NIST2, is the PQC algorithm natively implemented in the 5G SIM and used by Cryptosmart application to encrypt the communication.

“Building defences against threats that do not yet exist may appear to be a daunting task. That is exactly the prospect that the global cybersecurity community faces with the impending arrival of quantum computing. The post-quantum era is still years away, but as quantum computing becomes more prevalent, practicing crypto agility now with such pilots and trials are helping Thales and its customers get prepared” said Philippe KERYER, Executive Vice President Strategy & Technology at Thales.

1 Computers that can perform certain tasks much faster than today's computers on a large scale.
2https://www.nist.gov/news-events/news/2022/07/nist-announces-first-four-quantum-resistant-cryptographic-algorithms

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.

The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Digital Identity & Security
Thales unveils three quantum technologies set to revolutionise the world of tomorrow | Thales Group
Business Data Protection and Cybersecurity | Ercom

Permalink
https://www.aetoswire.com/en/news/3103202331439
Contacts
PRESS CONTACT

Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34

(BUSINESS WIRE) -- AGCO (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, infrastructure and precision ag technology, today released its 2022 Sustainability Report. The report showcases AGCO’s progress on environmental, social and governance issues as it strives to deliver farmer-focused solutions to sustainably feed our world.

“AGCO is delivering on its sustainability commitments, from industry-leading innovation to improve sustainability outcomes for farmers, to decarbonizing our products and operations, to offering our talented, diverse employees a safer, more engaging workplace. I am proud of the progress we’re making, and I am committed to accelerating progress as we work together to help farmers sustainably feed our world,” said Eric Hansotia, AGCO Chairman, President and CEO.

Innovating for farmers

Whether it is innovating for farmer customers with intelligent, network-connected tractors that reduce soil compaction by limiting repeated machinery passes in the field, or precision technologies that enable farmers to sequester carbon, AGCO’s global brands help farmers enhance the health and resilience of their soil. In 2022, Precision Planting introduced Radicle Agronomics™, a game-changing set of soil-analysis tools for agronomists, and Radicle Lab™, the world’s first fully automated soil laboratory designed to greatly improve the precision and timeliness of soil sampling.

Decarbonization

Key to AGCO’s sustainability commitment is helping farmers grow profitably and sustainably. AGCO’s brands offer groundbreaking products and technologies to sharply reduce or eliminate emissions from farm machinery. The recently launched AGCO Power CORE™ engines reach new heights of efficiency and are compatible with renewable diesel, enabling up to 90% reduction in greenhouse gas emissions. The fully electric Fendt e100 tractor is planned for launch in 2024.

AGCO is also decarbonizing its operations. In 2022, AGCO exceeded Scope 1 and 2 targets three years ahead of schedule by reducing the emissions intensity of manufacturing operations by 31% compared to the 2020 baseline. A detailed assessment of Scope 3 value chain emissions is complete, and product management, engineering and supply chain leaders are working together to define the long-term decarbonization roadmap.

Our People

Creating outstanding products and services for farmers starts with creating a work environment where employees can grow and thrive. AGCO actively seeks and responds to employee feedback through its annual ‘Voices’ survey. Nearly 20,000 employees shared their voice in 2002, with 88% sharing they are proud to work for AGCO.

Safety, health, and well-being serve as the foundation of the employee experience. AGCO’s safety incident rate is decreasing year-over-year, with a 14% decrease in 2022. AGCO has set a new goal to achieve a total incident rate below 1.5 by 2025.

Visit AGCO’s 2022 Sustainability Report for more information on these and other key sustainability initiatives.

About AGCO

AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005749/en/

Permalink
https://aetoswire.com/en/news/3003202331418
Contacts
Aryn Drawdy
Communications Director
Aryn.Drawdy@agcocorp.com

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus 10% Receiving Placebo.¹
−Superiority over Placebo Was Also Demonstrated at Week 34, with 35% of Vedolizumab Patients Achieving Remission Compared with 18% on Placebo.¹

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis. The NEJM article is titled “Vedolizumab for the Treatment of Chronic Pouchitis”.

A potentially curative surgical option for ulcerative colitis (UC) is total proctocolectomy, followed by creation of an ileal pouch anal anastomosis (IPAA) to aid in stool retention. Inflammation of the ileal pouch, pouchitis, can cause fecal incontinence, abdominal discomfort, and bleeding.2 Chronic pouchitis, defined by symptom duration greater than four weeks, can develop in up to one-fifth of these patients.3

The published results showed the Phase 4 EARNEST study met its primary efficacy endpoint of clinical and endoscopic remission, as measured by modified pouchitis disease activity index (mPDAI), at Week 14 in 31% of participants (16 out of 51) receiving vedolizumab versus 10% (5 out of 51) receiving placebo (95% CI: 5 to 38 percentage point [p.p.] difference; p=0.01). This improved outcome compared with placebo was also seen at the equivalent secondary endpoint at Week 34 (35% of vedolizumab patients [18 out of 51] achieved mPDAI remission compared with 18% [9 out of 51] on placebo [95% CI: 0 to 35 p.p. difference]).1

“Pouchitis is relatively common following pouch surgery for people with ulcerative colitis,” said Professor Simon Travis, Translational Gastroenterology Unit and Kennedy Institute, University of Oxford. “Demonstrating the efficacy of a biologic treatment for this inflammatory condition is important for a group of patients who have previously had no treatment option once antibiotics are no longer effective.”

Beyond mPDAI remission, patients receiving vedolizumab also demonstrated improved clinical response at both Week 14 and Week 34 over placebo, with a difference at Week 14 of 30 p.p. (95% CI, 8 to 48), and a Week 34 difference of 22 p.p. (95% CI, 2 to 40). Serious adverse events occurred in 6% (3 out of 51) and 8% (4 out of 51) of patients in the vedolizumab and placebo groups, respectively.1 No new safety signals were identified. The publication concluded that vedolizumab was more effective than placebo for inducing remission in chronic pouchitis after IPAA for patients with UC.

“We are committed to advancing treatment and care for patients living with debilitating inflammatory gastrointestinal conditions such as active chronic pouchitis,” said Marcelo Freire, Vice President, Global Medical Affairs, Therapeutic Area Head, Gastroenterology, Takeda. “The publication of the latest results from the EARNEST study in the New England Journal of Medicine is great recognition of the work we are doing to reduce the burden of this condition for patients.”

Vedolizumab is indicated only in the European Union for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and IPAA for UC and have had an inadequate response with or lost response to antibiotic therapy.4

In the United States, vedolizumab is indicated in adults for the treatment of moderately to severely active UC and Crohn’s disease (CD).5

About Pouchitis

Patients with ulcerative colitis (UC) may require removal of their colon and rectum (proctocolectomy), and the surgical creation of an ileal pouch (ileal pouch-anal anastomosis or IPAA) to aid stool retention. Pouchitis, where inflammation and irritation are seen in the lining of the new pouch, is the most common complication of an IPAA, affecting approximately 50% of patients with UC or familial adenomatous polyposis (FAP).3 Acute pouchitis may respond to antibiotic therapy, however there are currently no approved therapies indicated for active chronic pouchitis in the European Union, including the refractory form of pouchitis, which does not respond to antibiotic therapy, and where patients frequently relapse.3 Refractory pouchitis affects 10-15% of patients with pouchitis, and can have a considerable impact on their quality of life, causing fecal urgency, incontinence, straining during defecation, bleeding, abdominal or pelvic discomfort, fever and malaise.2,6,7

The prevalence of all pouchitis has been calculated to be 12 to 18 patients per 100,000 in the United States.8

About the EARNEST clinical trial

EARNEST is a randomized, double-blind, placebo-controlled multicenter study that evaluated the efficacy and safety of vedolizumab IV in the treatment of adult patients with UC who had undergone a proctocolectomy and IPAA, had developed active chronic pouchitis, and had inadequate response with or lost response to antibiotics therapy.9

About Vedolizumab

Vedolizumab is a gut-selective biologic and is approved for intravenous (IV) use in the United States and approved in both IV and subcutaneous (SC) formulations in Europe, Canada, Australia, Switzerland and Japan.4,5,10,11,12,13 It is a humanized monoclonal antibody designed to specifically antagonize the α4β7 integrin, inhibiting the binding of α4β7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).14 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.15 The α4β7 integrin is expressed on a subset of circulating white blood cells.14 These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).14,16,17 By inhibiting α4β7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.14

Vedolizumab is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist.4,5 Vedolizumab has been granted marketing authorization in over 70 countries, including the United States and European Union, with more than 1,000,000 patient years of exposure to date.18

Therapeutic Indications for vedolizumab

Ulcerative Colitis

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Crohn’s Disease

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Pouchitis

Vedolizumab IV is indicated in the EU for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) and have had an inadequate response with or lost response to antibiotic therapy.

Important Safety Information for vedolizumab

Contraindications

Hypersensitivity (such as dyspnea, bronchospasm, urticaria, flushing and increased heart rate) to the active substance or to any of the excipients.

Special Warnings and Special Precautions for Use

Intravenous vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering intravenous vedolizumab. Observe patients during infusion and until the infusion is complete.

Infusion-related reactions and Hypersensitivity Reactions

In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.

Injection Site Reactions (subcutaneous vedolizumab)

No clinically relevant differences in the overall safety profile and adverse events were observed in patients who received subcutaneous vedolizumab compared to the safety profile observed in clinical studies with intravenous vedolizumab with the exception of injection site reactions (with subcutaneous administration only). Injection-site reactions were mild or moderate in intensity, and none were reported as serious.

Infections

Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. No systemic immunosuppressive effect was noted in healthy subjects. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.

Malignancies

The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.

Prior and concurrent use of biological products

No vedolizumab clinical trial data are available for patients previously treated with natalizumab. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.

Vaccinations

Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.

Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, fatigue, injection site reactions and anaphylaxis.

Please consult with your local regulatory agency for approved labeling in your country.

For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO®.

For U.S. audiences, please see the full Prescribing Information, including Medication Guide for ENTYVIO® IV.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

1. Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med. 2023; 388:1191-1200
2. Schieffer KM, Williams ED, Yochum GS, et al. Review article: the pathogenesis of pouchitis. Aliment Pharmacol Ther. 2016;44:817–835.
3. Dalal RL, Shen B, Schwartz DA. Management of Pouchitis and Other Common Complications of the Pouch. Inflamm Bowel Dis. 2018;24:989-996.
4. Entyvio Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf. Last updated: October 2022. Last accessed: February 2023.
5. Entyvio Prescribing Information. Available at: https://general.takedapharm.com/ENTYVIOPI. Last updated: June 2022. Last accessed: March 2023.
6. Singh A, Khan F, Lopez R, et al. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep (Oxf). 2019;7:121-126.
7. Bär F, Kühbacher T, Dietrich NA, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47:581-587.
8. Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004;127(6):1809–1814.
9. A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis (EARNEST). Available at: https://clinicaltrials.gov/ct2/show/NCT02790138. Last updated: February 2022. Last accessed: March 2023.
10. Product Monograph including Patient Medication Information. Available at: https://assets-dam.takeda.com/raw/upload/v1662721781/legacy-dotcom/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/entyvio/ENTYVIO-PM-EN.pdf Last accessed: March 2023
11. Australian Product Information. Entyvio (vedolizumab). Available at: https://www.guildlink.com.au/gc/ws/tk/pi.cfm?product=tkpentyv11118#:~:text=The%20recommended%20dose%20regimen%20of,a%20dose%20at%20Week%2010. Last accessed: March 2023
12. Fachinformation Entyvio. Swissmedic. October 2020.
13. Takeda Receives Approval to Manufacture and Market Entyvio Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis. Available at: https://www.takeda.com/newsroom/newsreleases/2023/approval-to-manufacture-and-market-entyvio Last accessed: March 2023
14. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.
15. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97‑110.
16. Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298‑1312.
17. Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.
18. Takeda data on file (VV-SUP-116025): Vedolizumab Patient Exposure from Marketing Experience. July 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005306/en/

Permalink
https://www.aetoswire.com/en/news/3003202331420
Contacts
Media:

Japanese Media
Jun Saito
jun.saito@takeda.com
+81 (0) 3-3278-2325

U.S. and International Media
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924

 Blockchain-powered Nigerian fintech to integrate ThetaRay’s SONAR AI-powered technology to increase growth opportunities with a trusted service

Since its launch in 2022, Hayatna’s natural & healthy products have been winning the hearts of people in the country. Inspired to reward our consumers, Hayatna launched a mega promotion campaign from 22nd to 30th December 2022 across the UAE. The campaign was an extension of the brand promise “From our farms to your table”. It encouraged shoppers to buy Hayatna’s products worth AED 20 for a chance to win a stunning Jeep Wrangler & an entire year’s supply of groceries in the form of AED 10,000 vouchers. 

The promotion received an overwhelming response. Expressing pure joy with the big win, “Mohammad Sohaib” the winner of the Jeep Wrangler said, “I picked up Hayatna’s Lassi purely out of curiosity, and I'm obsessed with their entire ethnic range now. The Jeep is a massive surprise as I wasn’t expecting to win anything. It’s fantastic to see a brand give back to its consumers.”

Hayatna is committed to providing the most exceptional dairy and food products, which meet the nutritional expectations of the bustling population in the UAE. It brings to the table more than 150 products in 20+ categories that bear the hallmark of pure quality and sustainable innovation.

Hayatna’s ethnic product line falls under a unique category created to address the preferences and special flavors of a large and diverse consumer group. The dairy products are specially formulated based on popular taste and traditional values with a modern interpretation.

Permalink
https://aetoswire.com/en/news/2703202331331
Contacts
Tamer Saladin

00971523336190

Abu Dhabi University (ADU), one of the leading academic institutions in the Middle East and North Africa (MENA) region, has signed a memorandum of understanding (MoU) with Atkins, the leading global design, engineering and project management consultancy, that aims to enhance academic cooperation and exchange of scientific expertise between the two organizations in nuclear and energy sectors in the UAE.

As part of the five-year agreement, ADU will partner with Atkins to develop and deliver targeted trainings, activities and events that present educational programs about nuclear power and energy solutions and collaborate on research and scientific studies in the field. In addition, Atkins will provide training opportunities, including internships and project experience for ADU’s students, helping to build local capabilities and create job opportunities in the nuclear sector. The MoU was signed by Professor Ghassan Aouad, Chancellor, ADU, and David Haboubi, Head of Nuclear and Net Zero Energy, Middle East & Africa, at Atkins, a member of the SNC-Lavalin Group.

Professor Ghassan Aouad, Chancellor of ADU, said: “Abu Dhabi University is committed to enhancing research and innovation in key sectors, including Environmental Health and safety, nuclear and energy. This MoU with Atkins will provide valuable opportunities for our students and faculty to collaborate with industry experts and gain practical experience in these fields. We look forward to working closely with Atkins to develop educational programs and research initiatives that will contribute to the UAE’s sustainable development goals and build local capabilities.”

“With over 50 years’ presence in the Middle East, Atkins has played a key role in developing and enhancing the region’s nuclear and first-of-a-kind energy projects, which are critical to achieving a net zero carbon future,” said Haboubi. “We are truly excited to strengthen our working relationship with ADU through this collaboration, to further build the great talent that the University has by providing targeted research, projects and career opportunities.”

The UAE will host the 28th Conference of the Parties to the UN Framework Convention on Climate Change (COP28) in November 2023 at Expo City Dubai to unite the world towards agreement on bold, practical and ambitious solutions to the most pressing global challenge of our time. As host, the UAE will mobilize action around a “major course correction” to accelerate emissions reductions while ensuring energy security. Globally, SNC-Lavalin has developed the ‘Engineering Net Zero’ (ENZ) program, which focuses on leading the engineering industry to achieve Net Zero Carbon as rapidly as possible by helping clients manage climate risks and build climate resilience.

Abu Dhabi University is the largest private university in the UAE committed to providing graduates with the knowledge, skills, and mindset to become leaders of tomorrow, and engaging in research and innovation that make a difference to society. With five colleges offering over 50 undergraduate and postgraduate programs, campuses in Abu Dhabi, Al Ain, Dubai and Al Dhafra Region, and multiple affiliations with globally renowned institutions, ADU has the largest engineering college in the UAE, covering a diverse range of engineering and technology programs to more than 2,000 students.

The SNC-Lavalin Group, including Atkins and Faithful+Gould, has the biggest private nuclear capability in the world with a global track record of success in delivering nuclear projects and end-to-end engineering services for the entire project life cycle from the concept stage to design and technology development, including new-build programs, and from asset management through to end-of-life and waste management. Since 2011, Atkins has been a trusted advisor, engineering services, and project management partner on the Barakah Nuclear Energy Plant, the first nuclear power plant in the UAE. In line with its commitment to building local talent, Atkins has provided internship and training opportunities to over 30 Emiratis to gain technical expertise and practical knowledge in nuclear through mentorship and on-the-job training.

About Atkins

Atkins (www.atkinsglobal.com) is one of the world’s most respected design, engineering and project management     consultancies, employing over 19,000 people across the UK, North America, Middle East and Africa, Asia Pacific and Europe. We build long-term trusted partnerships to create a world where lives are enriched through the implementation of our ideas.

About SNC-Lavalin

Founded in 1911, SNC-Lavalin is a fully integrated professional services and project management company with offices around the world dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, technology and data to design, deliver and operate the most complex projects. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. – and delivered to clients in key strategic sectors such as Engineering Services, Nuclear, Operations & Maintenance and Capital. News and information are available at www.snclavalin.com or follow us on LinkedIn and Twitter.

About Abu Dhabi University:

Abu Dhabi University (ADU) is one of the region’s leading academic institutions and one of the UAE’s top three universities according to the Times Higher Rankings, working in line with the UAE Government’s National Agenda to deliver internationally accredited academic programs and world class research. Established in 2003, with campuses across Abu Dhabi, Dubai, Al Ain, and Al Dhafra, the University has a total enrollment of over 7,500 students from over 100 nationalities. Structured into Colleges of Arts and Sciences, Business, Engineering and Health Sciences, ADU offers over 50 undergraduate and graduate programs across a wide range of disciplines.

Abu Dhabi University is known for its cutting-edge, internationally accredited programs, additionally, ADU’s graduates are highly employable and work in high jobs and further studies with the university and other prestigious institutions. ADU provides its diverse faculty and students with world-class resources, facilities and learning opportunities that foster innovation and support researchers in the production of knowledge and research-based problem solving. The University enjoys strong international collaborations with leading academic institutions and with public and private sector organizations. With institutional accreditation from the US-based Western Association of Schools and Colleges’ Senior College and University Commission (WASC), ADU is ranked 301-350 universities in the world according to the 2023 Times Higher Education World University rankings and received 5 stars in the 2022 QS Stars rating. Abu Dhabi University is among the top three universities in the UAE in holding prestigious accreditations at institutional, college or subject level.

To know more about ADU, follow on Twitter, Instagram, Facebook, LinkedIn and YouTube.

Permalink
https://www.aetoswire.com/en/news/atkins29032023000565eng
Contacts
Zeina Kourki                                                                                                          

Manager, External Communications                                                                                

SNC-Lavalin - Middle East & Arica                                                                    

Zeina.Kourki@snclavalin.com                                                                         

Nour Shamaylah

Senior PR & Communications Specialist

Abu Dhabi University 

nour.shamaylah@adu.ac.ae

MADISON, Wis. - Wednesday, 29. March 2023 AETOSWire Print 

Type One Energy Group, Inc. capitalized with $29M, names new CEO

(BUSINESS WIRE) -- Type One Energy announced today the close of an over-subscribed $29 million financing round. This effort launches the company’s ambitious, partner-rich and capital-efficient FusionDirect program to commercialize its stellarator fusion technology.

Type One Energy’s technical foundations provide a powerful springboard to achieve its mission. Founded by several of the world’s leading stellarator experts, Type One Energy also brings concentrated experience from renowned fusion science institutions, including the University of Wisconsin-Madison in the U.S., the Max Planck Institute for Plasma Physics in Germany and the Massachusetts Institute of Technology (MIT) for its work on advanced magnet technology. The stellarator is a fusion technology characterized by inherently stable and steady-state operations. Related to tokamaks, stellarators do not, however, require massive circulating electric currents to assist in creating the magnetic fields used to confine their fusion plasma. This makes stellarator technology less physically complex and easier to translate into a practical fusion power plant.

Breakthrough Energy Ventures (BEV), TDK Ventures and Doral Energy Tech Ventures co-led the round with additional cleantech investment from Darco, the Grantham Foundation, MILFAM, Orbia Ventures, Shorewind Capital, TRIREC, VAHOCA and others.

The company’s unique FusionDirect commercialization program takes advantage of recent important breakthroughs to pursue a lowest-risk, shortest-schedule pathway to fusion energy. Improvements in stellarator fusion performance and plasma science work together with technical innovations in high-temperature superconducting (HTS) magnet technology and advanced manufacturing to spark Type One Energy’s launch of FusionDirect.

Type One’s commercialization program is being executed through a set of global partnerships with leading fusion science and technology research institutions, universities and industrial companies. These partnerships reflect the career-long collaborative relationships which the company’s industry-recognized technical leaders bring to Type One Energy. This technical leadership team includes Chief Technology Officer Dr. Thomas Sunn Pedersen, Chief Science Officer Dr. John Canik, Chief Engineer Dr. David Anderson, and Head of Stellarator Plasma Science Dr. Chris Hegna.

“Fusion is the ultimate energy source, and its successful commercialization will be a huge leap towards achieving clean and abundant energy for everyone,” said Carmichael Roberts, Breakthrough Energy Ventures. “Advances in stellarator science, including Type One Energy’s ability to execute a stellarator development project, provide the basis for a very exciting and promising path to practical fusion on the grid in the coming decades.”

With this announcement, the company will onboard former Breakthrough Energy Ventures’ (BEV) Senior Advisor on Fusion, Christofer Mowry, to serve as Chief Executive Officer (CEO). “Type One Energy represents a special opportunity. This team’s knowledge and credibility gives Type One the unique ability to effectively integrate recent global advances in stellarator-relevant technology and to deliver a fusion power plant without another costly, large-scale, science validation machine,” stated Type One Energy Group CEO Christofer Mowry. Previously, Mowry held the CEO position at General Fusion, where he scaled up the company and raised over $200M in private investment and government support from three countries.

“The science basis for stellarators has taken major leaps forward in the past several years. Through a combination of experimental demonstrations and the use of high-performance computing, the stage is set for the development of power plant scale machines,” said Dennis Whyte, Director of MIT’s Plasma Science and Fusion Center. “We look forward to collaborating with Type One Energy to realize the advantages of HTS high-field fusion magnets to their stellarator technology.”

“The world will need a source of high energy density low-carbon power in the coming decades to achieve energy transition and decarbonization. Among several startups that we have evaluated, Type One Energy is on a credible accelerated trajectory to commercialize a steady-state baseload fusion power plant. TDK Ventures is excited to back this highly accomplished leadership team,” said Tina Tosukhowong, Investment Director at TDK Ventures.

About Type One Energy Group

Type One Energy Group is mission-driven to provide sustainable, affordable fusion power to the world. The company was formed in 2019 by a team of globally-recognized fusion scientists with a strong track record of building state-of-art stellarator fusion machines, together with veteran business leaders experienced in successfully scaling companies and commercializing energy technologies. Type One Energy applies proven advanced manufacturing methods, modern computational physics and high-field superconducting magnets to develop its optimized stellarator fusion energy system. Its FusionDirect development program pursues the lowest-risk, shortest-schedule path to a fusion power plant over the coming decade, using a partner-intensive and capital-efficient strategy. For more information, visit https://www.typeoneenergy.com/.

About Breakthrough Energy Ventures (BEV)

Founded by Bill Gates and backed by many of the world’s top business leaders, BEV has raised more than $2 billion in committed capital to support cutting-edge companies that are leading the world to net-zero emissions. BEV is a purpose-built investment firm that is seeking to invest, launch and scale global companies that will eliminate GHG emissions throughout the economy as soon as possible. BEV seeks true breakthroughs and is committed to supporting these entrepreneurs and companies by bringing to bear a unique combination of technical, operational, market and policy expertise.

BEV is a part of Breakthrough Energy, a network of investment vehicles, philanthropic programs, policy advocacy and other activities committed to scaling the technologies we need to reach net-zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005074/en/

Permalink
https://www.aetoswire.com/en/news/2903202331402
Contacts
Catalina Carvajal, media@typeoneenergy.com, +1 646 480 0356